Nipro Corp (Nipro) develops, manufactures and markets pharmaceuticals, medical equipment and functional materials including glass, rubber and plastic products. The company’s products include renal products, interventional and anaesthesiology products, injection and infusion products, cardiopulmonary products, double bags, pre-filled syringes, and half-type kits among others. It offers contract manufacturing services of development, manufacturing of drug formulations, inspection, packaging, logistics and distribution services. Nipro also provides glass molding vials, ampoules, syringes, and cartridges; glass tubes for pharmaceuticals; glass-forming machinery; other parts of pharmaceutical packaging including rubber plugs; and glass bulbs for vacuum flasks. The company has sales offices in North America, South America, Europe, Asia and Africa. Nipro is headquartered in Osaka, Japan.
Headquarters
Japan
Address
3-9-3, Honjo-Nishi, Kita-Ku, Osaka-Shi, 531-8510
Website
www.nipro.co.jp
Telephone
81 6 63722331
No of Employees
35,251
Industry
Medical Equipment
Ticker Symbol & Exchange
8086 (TYO)
Revenue (2022)
$4.4B
EPS
XXX
Market Cap*
$1.3B
Net Profit Margin (2021)
XXX
212.2%
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Medical Related | Service: | PLW |
| Renal | Contract Manufacturing Services | PFS |
| Dialysis Machine | ||
| XXX | ||
| XXX | ||
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Contracts/Agreements | In May, the company's subsidiary Nipro Pharma Corp entered into contract manufacturing agreement with AstraZeneca to provide fill and finish process to AstraZeneca's vaxzevria, an intramuscular injection for COVID-19. |
| 2021 | Acquisitions/Mergers/Takeovers | In May, the company acquired Piramida, a Croatian pharmaceutical glass manufacturer. |
| 2021 | Corporate Changes/Expansions | In April, the company opened new sales office in Changchun, China. |
Competitor Comparison
| Key Parameters | Nipro Corp | Fresenius SE & Co KGaA | Chugai Pharmaceutical Co Ltd | Terumo Corp | Mitsubishi Tanabe Pharma Corp |
|---|---|---|---|---|---|
| Headquarters | Japan | Germany | Japan | Japan | Japan |
| City | Osaka-Shi | Bad Homburg Vor Der Hohe | Chuo-Ku | Shibuya-Ku | Osaka |
| State/Province | Osaka | - | Tokyo | Tokyo | Osaka |
| No. of Employees | 35,251 | 317,242 | 7,664 | 28,294 | 6,728 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yoshihiko Sano | President; Director | Executive Board | 2006 | - |
| Yasushi Ohyama | Managing Director | Senior Management | - | - |
| Kenichi Nishida | Managing Director | Senior Management | 2010 | - |
| Kazuhiko Sano | Managing Director | Senior Management | 2010 | - |
| Takehito Yogo | Managing Director | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer